Evaluation of the suppressing effect of Telmisarten on aneurysm development in hypertensive aortic aneurysm patients

Evaluation of the suppressing effect of Telmisarten on aneurysm development in hypertensive aortic aneurysm patients - TELME study

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003377

Enrollment

Registered

2010-03-25

Start date

2013-08-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypertensive aortic aneurysm patients

Interventions

Telmisarten any other ACE inhibitors and ARB

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: hypertensive aortic aneurysm patients with ACE inhibitors and ARB

Exclusion criteria

Exclusion criteria: Taboo symptom of Telmisarten Pregnant women Liver and renal function failure Minority

Design outcomes

Primary

Measure	Time frame
aneurysm development	—

Secondary

Measure	Time frame
Blood pressure Inflammatory markers in the blood Lipid abnormality evaluation	—

Countries

Japan

Contacts

Public ContactYoshikatsu Saiki

Tohoku university hospital Cardiovascular surgery

yoshisaiki@med.tohoku.ac.jp022-717-7222

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026